STERIS plc (STE) Q4 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with expanded EBIT margins and double-digit EPS growth. The Q&A session reveals operational improvements and strategic moves like the $1 billion buyback and tuck-in M&A, suggesting future growth. Despite some challenges, such as tough comps and weather impacts, management's optimistic guidance and strategic investments in high-margin areas indicate a positive outlook. The sentiment is further bolstered by the commitment to shareholder returns and operational efficiencies, supporting a positive stock price movement prediction.
Key Financial Performance
Total as reported revenue (Q4 FY2026) Grew 7%. Constant currency organic revenue grew 5% in the quarter, driven by volume as well as 230 basis points of price.
Gross margin (Q4 FY2026) 44%, down 30 basis points versus the prior year. Positive pricing helped mitigate the impact of higher tariffs and inflation.
EBIT margin (Q4 FY2026) 24.2% of revenue, 60 basis points below the fourth quarter last year, mainly driven by inflation and tariffs.
Incremental tariffs impact (Q4 FY2026) Approximately $10 million, below expectations due to lower volumes in materials and products sourced from outside the U.S.
Adjusted effective tax rate (Q4 FY2026) 25.4%, an increase from 23.5% in the fourth quarter last year, driven primarily by changes in geographic mix and unfavorable discrete items.
Adjusted net income (Q4 FY2026) $278.3 million. Earnings per diluted share from continuing operations were $2.83, a 3% increase over the prior year as the lower margin and higher tax rate limited earnings growth.
Capital expenditures (FY2026) $369 million.
Depreciation and amortization (FY2026) $486.5 million.
Total debt (FY2026) $1.9 billion. Gross debt to EBITDA at year-end was approximately 1.2x, well below the target of 2 to 2.5x.
Free cash flow (FY2026) $982.9 million, with year-over-year improvement driven primarily by an increase in earnings, which more than offset the significantly lower contribution from working capital in fiscal 2026 compared with fiscal 2025.
Revenue growth (FY2026) 9% as reported, 7% on a constant currency organic basis. Adjusted earnings per share grew 10% despite the 80 basis points of impact from tariffs on margins.
Healthcare segment revenue (FY2026) Grew 9% as reported and 8% from a constant currency organic perspective. Service grew 12%, consumables grew 7%, and capital equipment grew 6%.
AST segment revenue (FY2026) Grew 10% as reported and 7% constant currency organic. Services business grew 11% as reported or about 8% constant currency organic.
Life Sciences segment revenue (FY2026) Grew 9% as reported and 7% constant currency organic. Capital equipment grew 15%, consumables grew 8%, and services improved 5%.
Total company EBIT margins (FY2026) Expanded by 10 basis points to 23.3% despite incremental tariff costs of approximately $46 million, which trimmed margin by 80 basis points.
Adjusted earnings per diluted share (FY2026) $10.17, reflecting double-digit growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Healthcare Service Growth: Healthcare services grew 12%, driven by the breadth of the portfolio and commercial team performance.
Capital Equipment Growth: Capital equipment grew 6%, stabilizing after years of variability.
Life Sciences Capital Equipment Growth: Life Sciences capital equipment grew 15%, reflecting customer return to capital investment.
New Acquisitions: Two acquisitions were completed: MEDglas walls supplier integration and a family of GI products, contributing $45 million in revenue for fiscal 2027.
Revenue Growth: Total company revenue grew 9% in fiscal 2026, reaching approximately $6 billion.
Healthcare Revenue Milestone: Healthcare segment reached $4 billion in revenue and $1 billion in operating income.
AST Revenue Milestone: AST segment exceeded $1 billion in revenue and $500 million in operating profit.
Life Sciences Revenue Milestone: Life Sciences segment exceeded $250 million in operating profit for the first time.
Gross Margin: Gross margin for Q4 was 44%, down 30 basis points due to tariffs and inflation.
EBIT Margin: EBIT margin for Q4 was 24.2%, a high for fiscal 2026, despite being 60 basis points below last year.
Free Cash Flow: Free cash flow for fiscal 2026 was $982.9 million, driven by increased earnings.
Capital Expenditures: Capital expenditures for fiscal 2026 totaled $369 million, with a focus on AST expansion projects.
AI Integration: A multiyear project to upgrade service workflows with AI to improve quality, productivity, and customer experience.
New Manufacturing Plant: A new sterility assurance manufacturing plant will be built in Mentor, Ohio, consolidating U.S. production into a state-of-the-art facility by the end of 2027.
Share Buyback Program: A new $1 billion share buyback authorization was approved, with plans to repurchase $200-$300 million annually.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs and Inflation: Incremental tariffs and inflation have negatively impacted gross margins and EBIT margins, with tariffs alone costing approximately $46 million in fiscal 2026 and expected to remain flat in fiscal 2027.
Tax Rate Increases: The adjusted effective tax rate increased to 24.4% in fiscal 2026 and is expected to rise further to 25% in fiscal 2027 due to geographic profit mix and withholding taxes, which could pressure financial performance.
Supply Chain Challenges: Although supply chain challenges have improved, working capital is expected to grow in line with volume, which could strain operational efficiency.
AST Segment Performance: Procedure volumes outside the U.S. continue to lag, impacting the Applied Sterilization Technologies (AST) segment, which also faced softness in the second half of fiscal 2026.
Med-Tech Customer Inventory Management: Med-tech customers are carefully managing inventory levels, leading to a cautious outlook for the AST segment in fiscal 2027.
Weather-Related Disruptions: Severe snowstorms in the U.S. early in the calendar year negatively impacted service volumes in the AST segment during fiscal 2026.
Capital Expenditure Shifts: The company is shifting capital spending priorities, including a $60 million investment in a new manufacturing plant, which could temporarily increase costs and operational complexity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal 2027 Revenue Growth: As-reported revenue is expected to grow 7% to 8%, with constant currency organic revenue growth anticipated at 6% to 7%. Foreign currency changes are expected to be slightly favorable.
Segment Revenue Growth: Healthcare and Life Sciences segments are projected to grow 6% to 7% constant currency organic, while AST is expected to grow 7% to 8%.
Earnings Per Share (EPS): Fiscal 2027 EPS is projected to be in the range of $11.10 to $11.30, reflecting growth of 9% to 11% over fiscal 2026.
EBIT Margins: EBIT margins are anticipated to expand by approximately 50 basis points, assuming flat tariff spending and benefits from incentive compensation programs.
Free Cash Flow and Capital Expenditures: Free cash flow is expected to be $850 million, with capital expenditures projected at $375 million.
Strategic Investments: Investments include a new sterility assurance manufacturing plant in Mentor, Ohio, with $60 million allocated over two years, expected to be operational by the end of calendar 2027. Additional investments in AI-driven technologies to enhance service workflows in Healthcare and Life Sciences segments.
Acquisitions Contribution: Two recent acquisitions are expected to contribute approximately $45 million in combined revenues for fiscal 2027.
Procedure Volume Growth: U.S. procedure volume is expected to grow mid-single digits, consistent with fiscal 2026, while international procedure volumes are expected to lag.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Increase: The company increased the quarterly dividend by $0.06 to $0.63, marking the 20th consecutive year of dividend growth.
Share Buyback Program: The company used $225 million for share buybacks in fiscal 2026. Additionally, the Board has approved a new $1 billion buyback authorization, with plans to consistently buy back shares in the range of $200 million to $300 million per year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the FY '27 earnings guidance and the factors affecting it?
A:Management expects operating margin expansion of approximately 50 bps at the high end of the range. Factors include operational improvements, sell-through of higher-margin consumables, favorable tariff changes, freight recovery pricing, and minimal exposure to oil-driven costs (20% of COGS).
Q:How is the company addressing difficult comps in AST service and organic growth phasing?
A:Management expects a slower start in the first half of FY '27 due to tough AST comps, with significant improvement in Q3 and easier comps in Q4. Snowstorms in Q4 FY '26 caused a 150-200 bps growth loss.
Q:What is the expectation for the USMCA renegotiation and its impact on guidance?
A:Management assumes no changes in USMCA for FY '27, expecting it to move into an annual continual review phase.
Q:What is the impact of the rollback of ethylene oxide regulations on STERIS?
A:There is no significant financial impact as the company has already upgraded its facilities. Timing on compliance may be extended.
Q:What is the significance of the $1 billion buyback and tuck-in M&A in Healthcare?
A:The buyback reflects a commitment to consistent repurchases despite withholding tax costs. Tuck-in M&A in Healthcare is expected to have a material impact, contributing close to 100 basis points to fiscal performance.
Q:What caused the lumpiness in AST capital component in Q4 FY '26?
A:The lumpiness is due to the timing of large equipment orders, which can vary significantly between quarters.
Q:What trends were observed in AST volumes and med-tech customer inventory levels?
A:AST organic volume was lower than expected in the last two quarters of FY '26 due to snowstorms and med-tech customers reducing inventory levels. Procedure rates and med-tech revenue growth remain strong.
Q:How should capital equipment revenue and backlog progress through FY '27?
A:Capital equipment revenue and backlog are expected to follow a cyclical pattern, with high shipments in Q4 FY '26 causing a backlog drain. Orders remain solid, supported by demand from healthcare systems.
Q:What are the motivations and expected efficiencies from consolidating sterility assurance facilities?
A:The consolidation is driven by capacity needs and the opportunity to create a nearly fully automated manufacturing facility. This supports long-term growth in a high-margin business.
Q:What is the expected recovery of lost AST volume due to weather in Q4 FY '26?
A:Management finds it difficult to quantify the recovery but expects the volume to return over time as deferred surgical procedures are performed.
Q:What are the tariff and bonus tailwinds factored into FY '27 guidance?
A:FY '26 had a $46 million incremental tariff headwind, with a total spend of $60-65 million modeled for FY '27. No refunds are included in guidance. A $20 million bonus tailwind is modeled due to overachievement in FY '26.
Q:What is the focus on compliance and standardization in sterile processing?
A:STERIS is enhancing compliance in sterile processing by integrating systems that track and trace compliance, provide access to IFUs, and eliminate unnecessary steps for customers.
Q:What is the approach to the larger buyback authorization?
A:Management plans to use $200-300 million for buybacks, balancing withholding tax costs and cash position. A measured approach is preferred to ensure accretion over time.
Q:What are the inflationary pressures and supply chain visibility for FY '27?
A:Management expects routine labor inflation and upward pressure on raw materials and freight costs due to oil prices. Supply chain resilience has improved, with strategic inventory and reduced single-source supply risks.
Q:What is the outlook for Life Sciences customers and reshoring trends?
A:Life Sciences is recovering from a COVID boom-bust cycle, with strong capital buying patterns and reshoring activity. Consumables are a high-margin growth driver, while smaller investments remain limited.
Q:What is the significance of the MEDglas and GI consumables acquisitions?
A:MEDglas enhances OR and SPD aesthetics and cleaning efficiency but has low margins. GI consumables add sales reps and inventory, supporting growth in GI products.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear answer on the expected recovery timing of lost AST volume due to weather in Q4 FY '26, stating it is difficult to quantify and depends on deferred surgical procedures being performed.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chad today
Communications Chad
Financial Results
States cash
United States
Winter Investor
accordance capital
adjustment withholding
allocation priority
amortization balance
border capital
buyback program
capital allocation
capital context
capital line
capital movement
cash border
cash share
chain challenge
challenge capital
commitment capital
context capital
contribution capital
dividend cash
estimate Capital
expectation volume
factor mix
flow improvement
flow pressure
high basis
increase contribution
increase margin
inflation margin
inventory reduction
mix item
pressure tax
rate increase
withholding tax
STE Transcript
STERIS plc (STE) Q4 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights strong financial performance with expanded EBIT margins and double-digit EPS growth. The Q&A session reveals operational improvements and strategic moves like the $1 billion buyback and tuck-in M&A, suggesting future growth. Despite some challenges, such as tough comps and weather impacts, management's optimistic guidance and strategic investments in high-margin areas indicate a positive outlook. The sentiment is further bolstered by the commitment to shareholder returns and operational efficiencies, supporting a positive stock price movement prediction.
STERIS plc (STE) Q3 2026 Earnings Call Transcript
Positive2-5
The earnings call reveals solid financial performance, with increased revenue and improved EBIT margins in key segments. Despite some margin declines due to tariffs, the overall outlook remains optimistic, supported by strong growth in Life Sciences and AST. The Q&A section highlights effective mitigation strategies for tariffs and positive market trends, such as capacity expansions. The increase in earnings and free cash flow guidance further supports a positive sentiment. However, the lack of major M&A and conservative cash flow guidance slightly temper the outlook, leading to a positive but not strong positive prediction.
STERIS plc (STE) Q2 2026 Earnings Call Transcript
Positive11-6
The earnings call reflects strong financial performance with a 15% increase in EPS and robust free cash flow. The company anticipates 8-9% revenue growth and maintains strong growth across segments. Positive factors include increased EBIT margins and solid growth in healthcare and AST services. Despite headwinds from tariffs and inflation, the guidance remains optimistic, supported by strategic expansions and stable demand. The Q&A session reinforced management's confidence in sustained growth, though some responses lacked detail. Given these factors, a positive stock price movement is expected.
STERIS plc (STE) Q1 2026 Earnings Call Transcript
Positive8-7
The earnings call indicates strong financial performance with increased net income, free cash flow, and dividends. Despite tariff challenges, the company maintains growth expectations and reports strong order growth across segments. The Q&A reveals confidence in market positions and future prospects, with no major concerns raised by analysts. The positive sentiment is supported by organic revenue growth, margin improvements, and strategic cash management plans, suggesting a likely stock price increase in the short term.
STE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
